Last update 25 Apr 2025

RO-7496353

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
RG 6440, RG-6440, RG6440
+ [5]
Target
Action
inhibitors
Mechanism
TGF-β1 inhibitors(Transforming growth factor beta 1 inhibitors)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic Solid TumorPhase 1
United States
02 Oct 2023
Metastatic Solid TumorPhase 1
United States
02 Oct 2023
Metastatic Solid TumorPhase 1
Japan
02 Oct 2023
Metastatic Solid TumorPhase 1
Japan
02 Oct 2023
Metastatic Solid TumorPhase 1
Australia
02 Oct 2023
Metastatic Solid TumorPhase 1
Australia
02 Oct 2023
Metastatic Solid TumorPhase 1
Brazil
02 Oct 2023
Metastatic Solid TumorPhase 1
Brazil
02 Oct 2023
Metastatic Solid TumorPhase 1
Italy
02 Oct 2023
Metastatic Solid TumorPhase 1
Italy
02 Oct 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
-
sgrqbmzxdx(uxjlyoffey) = One dose-limiting toxicity (liver disorder) was seen with SOF10 (600 mg) + atezolizumab xdrepvwffy (jyuvmxpske )
-
14 Sep 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free